Lathyrus Sativas Seed

Dosage for Lathyrus Sativas Seed extract is highly individualized and must be determined by a specialist in allergy and immunology. There is no 'standard' dose that applies to all patients.

Diagnostic Testing

• Skin Prick Test: Usually involves a single drop of a 1:10 or 1:20 w/v extract applied to the skin, followed by a puncture. Results are read in 15–20 minutes.
• Intradermal Testing: If the prick test is negative but a high clinical suspicion remains, a dose of 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) may be injected into the skin.

Immunotherapy (SCIT)

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution). Doses are increased weekly or bi-weekly as tolerated by the patient.
• Maintenance Phase: Once the 'top dose' is reached (the highest dose the patient can tolerate without a systemic reaction), the interval between injections is increased to every 2–4 weeks. A common maintenance volume is 0.5 mL of a 1:10 or 1:20 w/v concentration.

Lathyrus Sativas Seed extract can be used in children, but the decision must be made with extreme caution.

• Age Considerations: Immunotherapy is rarely started in children under the age of 5 due to the difficulty of communicating systemic symptoms.
• Dosing: The dosing schedule for children is generally similar to adults but may be adjusted based on the child's weight and the severity of their allergic sensitivity. Pediatric patients must be monitored even more closely for signs of anaphylaxis.

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the proteins are not primarily cleared by the kidneys in a manner that affects safety. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are defined for hepatic impairment. The metabolic processing of allergenic proteins is independent of liver function.

Elderly Patients

Elderly patients may have a higher risk of complications if a systemic reaction occurs (e.g., due to pre-existing cardiovascular disease). Dosing may be more conservative, and the 'build-up' phase may be slower.

Lathyrus Sativas Seed extract is never for self-administration at home. It must be administered in a clinical setting equipped with emergency supplies.

• Administration: Subcutaneous injection is typically given in the posterior aspect of the upper arm.
• Observation: Patients must remain in the doctor's office for at least 30 minutes after every injection to monitor for anaphylaxis.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Freezing will denature the proteins and render the extract useless or dangerous.

In immunotherapy, timing is critical.

• If a dose is missed by a few days, the same dose may often be given.
• If a dose is missed by several weeks, the dose may need to be reduced to avoid a reaction, as the patient's 'protection' may have waned. Your allergist will follow a specific 'gap-filling' protocol.

An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration higher than the patient's current tolerance level.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, and abdominal cramping.
• Emergency Measures: Immediate administration of epinephrine (0.3mg IM for adults), oxygen, IV fluids, and potentially antihistamines or corticosteroids. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter your injection schedule without medical guidance.

Most patients undergoing skin testing or immunotherapy with Lathyrus Sativas Seed extract will experience some form of local reaction. These are generally considered expected and manageable.

• Local Wheal and Flare: During testing, a small itchy bump (wheal) surrounded by redness (flare) is the intended result. This usually fades within 1–2 hours.
• Injection Site Swelling: In immunotherapy, it is common to have a 'local' reaction at the site of the shot. This may feel like a mosquito bite—red, itchy, and slightly warm. These typically resolve within 24 hours.
• Mild Fatigue: Some patients report feeling slightly tired or 'run down' for a few hours following an immunotherapy injection as the immune system processes the allergen.

• Large Local Reactions (LLR): Swelling at the injection site that exceeds 2 inches (5 cm) in diameter. These can be uncomfortable and may require the application of ice or the use of an oral antihistamine.
• Generalized Pruritus: Itching that occurs away from the injection site, such as on the palms of the hands or the scalp.
• Nasal Congestion or Sneezing: A mild 'flare-up' of hay fever symptoms shortly after the injection.

• Urticaria (Hives): The development of itchy welts across various parts of the body.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Cough: A dry, hacking cough that may signal the beginning of a systemic respiratory reaction.

> Warning: Stop the administration process and call your doctor or emergency services immediately if you experience any of the following symptoms of Anaphylaxis:

1. 1Difficulty Breathing: Wheezing, chest tightness, or a feeling of 'air hunger.'
2. 2Throat Swelling: A 'lump in the throat,' hoarseness, or difficulty swallowing.
3. 3Hypotension: Feeling faint, dizzy, or passing out (this indicates a dangerous drop in blood pressure).
4. 4Rapid Pulse: A racing heart accompanied by a sense of 'impending doom.'
5. 5Cyanosis: A bluish tint to the lips or fingernails, indicating lack of oxygen.
6. 6Severe Gastrointestinal Distress: Sudden, violent vomiting or diarrhea immediately following an injection.

There are no known long-term systemic toxicities associated with the chronic use of Lathyrus Sativas Seed allergenic extracts. The primary 'long-term' effect is the desired modulation of the immune system. However, patients with poor lung function (uncontrolled asthma) may experience a gradual decline in respiratory health if they suffer frequent, unrecognized mild bronchospasms following injections.

Allergenic extracts, including Lathyrus Sativas Seed, carry a Class-Wide Black Box Warning regarding the risk of severe anaphylaxis.

• Summary: This product can cause severe, life-threatening allergic reactions. It must only be administered in a healthcare setting by personnel trained in the management of anaphylaxis. Patients with unstable asthma are at a significantly higher risk for fatal reactions. Patients must be observed for at least 30 minutes post-injection. Some reactions may be 'delayed' and occur after the patient leaves the office; therefore, many providers require patients to carry an epinephrine auto-injector (e.g., EpiPen).

Report any unusual symptoms, even if they seem mild, to your healthcare provider before your next scheduled dose.

Lathyrus Sativas Seed extract is a potent biological agent. Its use requires a careful balance of risk and benefit. The most critical safety consideration is the prevention and management of anaphylaxis. Patients must be in a stable state of health before receiving any dose. If you are feeling ill, have a fever, or are experiencing an asthma flare-up, your injection should be postponed.

WARNING: SEVERE ALLERGIC REACTIONS

Lathyrus Sativas Seed extract can cause life-threatening systemic reactions, including anaphylaxis.

• Administration must occur in a facility equipped to treat such reactions.
• Patients must be observed for 30 minutes.
• Patients with severe or unstable asthma are at increased risk of death.
• Certain medications (e.g., beta-blockers) may make reactions more difficult to treat.

• Anaphylaxis Risk: This is the primary risk. Reactions can occur even in patients who have tolerated previous doses for years.
• Asthma Status: If your asthma is not well-controlled (e.g., you are using your rescue inhaler more than twice a week), you must inform your doctor. Immunotherapy should not be administered during an asthma exacerbation.
• Cardiovascular Disease: Patients with significant heart disease may not be able to tolerate the stress of a systemic reaction or the effects of the epinephrine used to treat it.
• Autoimmune Disorders: There is a theoretical risk that immunotherapy could worsen certain autoimmune conditions, though data is limited. A risk-benefit analysis is required.

• Pre-Injection Screening: Before every dose, your provider will ask about your health, any reactions to the previous dose, and current medications.
• Peak Flow Meter: For asthmatic patients, a peak flow reading may be required before the injection to ensure lung function is at its baseline.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic.
• Skin Test Monitoring: During diagnostic testing, the skin is monitored for 15-20 minutes for the development of a wheal.

Generally, Lathyrus Sativas Seed extract does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (opening of blood vessels), which can potentially increase the rate of allergen absorption and increase the risk or severity of a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping early may result in the return of allergic symptoms. If you need to stop, no 'tapering' is required for the drug itself, but your allergy symptoms will no longer be suppressed by the treatment.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Lathyrus Sativas Seed.

While there are few absolute contraindications, the following combinations are generally avoided due to extreme safety risks:

• Beta-Blockers (including eye drops): Drugs like propranolol, metoprolol, or timolol eye drops can block the effects of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction to Lathyrus Sativas Seed extract, the standard treatment (epinephrine) may not work, leading to a potentially fatal outcome.
• Unstable Asthma Medications: If a patient requires high-dose oral steroids or frequent emergency visits for asthma, the extract should not be used.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (like lisinopril) may be at a higher risk for more severe systemic reactions during immunotherapy.
• MAO Inhibitors: Medications used for depression (like phenelzine) can interfere with the metabolism of epinephrine, potentially complicating the treatment of a reaction.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), or diphenhydramine (Benadryl) will mask skin test results. These must be discontinued for 3–7 days before diagnostic testing with Lathyrus Sativas Seed extract.
• Tricyclic Antidepressants: Similar to MAOIs, these can potentiate the effects of epinephrine, requiring careful management during an emergency.

• Cross-Reactive Foods: Patients allergic to Lathyrus Sativas Seed may also be allergic to other legumes (peanuts, lentils, chickpeas). Consuming these foods shortly before or after an injection may increase the 'allergic load' and trigger a reaction.
• Alcohol: As mentioned, alcohol can increase the speed of allergen absorption and should be avoided for 24 hours around the time of injection.

• St. John's Wort: May affect the metabolism of various medications used in emergency settings.
• Feverfew/Ginkgo: These have mild anti-platelet effects but generally do not interfere directly with the extract; however, patients should always disclose their use.

• Skin Testing: The extract itself is the 'test.' It does not typically interfere with blood labs (like CBC or Chem-7).
• Total IgE/Specific IgE: Immunotherapy will eventually lower specific IgE levels toward Lathyrus Sativas Seed, which is a sign of treatment efficacy.

For each major interaction, the mechanism is usually pharmacodynamic (affecting the body's response to the drug or the rescue medication) rather than pharmacokinetic (affecting the drug's levels in the blood).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Lathyrus Sativas Seed extract must NEVER be used in the following circumstances:

1. 1Previous Severe Systemic Reaction: If a patient has had a life-threatening reaction to this specific extract in the past, the risk of re-administration usually outweighs the benefit.
2. 2Uncontrolled or Severe Asthma: Patients with an FEV1 (Forced Expiratory Volume) persistently below 70% of predicted value or those with unstable symptoms are at high risk of death from immunotherapy-induced bronchospasm.
3. 3Acute Infection: Injections should not be given during an active febrile illness, as this 'primes' the immune system and increases the risk of a reaction.
4. 4Malignancy or Immunodeficiency: Patients with active cancer or severe primary immunodeficiencies are generally not candidates for immunotherapy.

These conditions require a careful risk-benefit analysis by the specialist:

• Beta-Blocker Therapy: If the patient cannot be switched to an alternative blood pressure medication, immunotherapy is often withheld.
• Pregnancy (Initiation): While maintenance immunotherapy can often be continued during pregnancy, it is standard practice not to start a new build-up phase due to the risk of anaphylaxis-induced fetal hypoxia.
• Severe Atopic Dermatitis: Extensive skin disease may make it impossible to find a clear area for skin testing.

Patients should be aware of 'Legume Cross-Reactivity.' The proteins in Lathyrus Sativas Seed are structurally similar to those in:

• Peanuts
• Soybeans
• Lentils
• Peas

If you have a known severe allergy to any of these, you may be at a higher risk of reacting to the Lathyrus Sativas Seed extract.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Lathyrus Sativas Seed.

• Risk Summary: Lathyrus Sativas Seed extract is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.
• Clinical Considerations: The primary risk to the fetus is maternal anaphylaxis, which can lead to a sudden drop in blood pressure and oxygen delivery to the placenta, potentially causing fetal distress or death.
• Recommendation: Most allergists will not start a new course of immunotherapy during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment may be continued, often at a reduced or non-increasing dose.

• Passage into Milk: It is highly unlikely that the large proteins in the extract would pass into breast milk in any significant or active form.
• Safety: Breastfeeding is generally considered safe during immunotherapy. There are no known adverse effects on the nursing infant.

• Approval: Extracts are used in children, but safety data is most robust for children ages 5 and older.
• Challenges: Younger children may not be able to articulate the early symptoms of a systemic reaction (like an itchy throat or 'funny feeling'), making administration riskier.
• Growth: There is no evidence that allergenic immunotherapy affects growth or development in children.

• Risk Profile: Patients over 65 are at a higher risk for complications from systemic reactions. They are more likely to have underlying cardiovascular disease or be taking medications (like beta-blockers) that complicate the treatment of anaphylaxis.
• Assessment: A thorough cardiac evaluation is often recommended for elderly patients before beginning immunotherapy.

• Adjustment: No dose adjustment is needed for patients with kidney disease. However, if the patient is on dialysis, the timing of the injection should be coordinated with their dialysis schedule to ensure they are at their most stable state.

• Adjustment: No dose adjustment is needed for patients with liver disease. The processing of these proteins does not rely on hepatic metabolism.

> Important: Special populations require individualized medical assessment and more frequent monitoring during the course of treatment.

Lathyrus Sativas Seed extract functions as an immunomodulator. Its molecular mechanism depends on the context of its use:

1. 1Diagnostic Phase: The extract contains specific proteins (allergens) that bind to the Fab portion of IgE antibodies already present on the patient's mast cells. This binding causes the IgE receptors (FcεRI) to cluster, triggering a signal transduction cascade involving tyrosine kinases (like Syk). This leads to the release of pre-formed mediators like histamine from intracellular granules.

1. 1Therapeutic Phase (Immunotherapy): Repeated exposure to increasing doses of these proteins induces 'peripheral tolerance.' This involves:

• T-cell Anergy: Reducing the responsiveness of allergen-specific Th2 cells.
• T-reg Induction: Increasing the production of Regulatory T-cells that secrete IL-10 and TGF-β, which suppress allergic inflammation.
• B-cell Switching: Inducing B-cells to produce IgG4 instead of IgE. IgG4 acts as a 'blocking antibody,' intercepting the allergen before it can reach the IgE on mast cells.

• Onset of Action: For skin testing, the onset is rapid (15–20 minutes). For immunotherapy, symptomatic relief usually begins after 3–6 months of treatment, but full effect requires reaching the maintenance dose.
• Duration of Effect: A single skin test has a duration of a few hours. A completed 3-to-5-year course of immunotherapy can provide relief for many years or even a lifetime.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | Primarily to IgE and IgG antibodies |

| Half-life | Proteins degraded within hours; Immunologic effect lasts years |

| Tmax | 15-30 minutes (local tissue concentration) |

| Metabolism | Proteolytic degradation by lysosomes |

| Excretion | Cellular metabolic pathways |

• Composition: A complex mixture of proteins, glycoproteins, and lipids. The primary allergens are typically globulin and albumin proteins found in the seed.
• Solubility: Soluble in aqueous solutions; often provided in a 50% glycerin/water buffer for stability.
• Molecular Weight: Varies widely (from 10 kDa to over 70 kDa for various protein fractions).

Lathyrus Sativas Seed is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergenics, which includes extracts for pollens, molds, animal dander, and insects.